BSH/UKMS Guidelines
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline.
Published on B-S-H website March 2021
Please find the link below to the most recent publication from NICE outlining Interim treatment change options during the COVID-19 pandemic issued on.  It is endorsed by NHS England. Some of options proposed for multiple myeloma are:
- Allow oral pomalidomide with dexamethasone as second- or third-line therapy instead of intravenous treatments in patients previously treated with lenalidomide to reduce the need for chemotherapy and reduce admissions and risk of neutropenia.
- Allow first-line lenalidomide and dexamethasone for transplant eligible myeloma patients in preference to regimens that require more hospital attendances and parenteral administrations to reduce toxicity of treatment and number of admissions required for treatment.
- Allow second-line lenalidomide and dexamethasone for patients who have not been previously treated with bortezomib.
Please see link below to access the full document.
Interim treatment change options during the COVID-19 pandemic, endorsed by NHS EnglandÂ
UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak
It is clear that the current outbreak is going to impact the ability to deliver healthcare for some months to come. This is especially the case for systemic anti-cancer therapy.
To try and mitigate the impact of changing capacity, and to minimise the risk that the immunosppressive effects of myeloma therapy has, the guidance in the below document has been compiled on 25th March 2020 to help support myeloma doctors in their decision-making and treatment planning.
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline.
Published on B-S-H website March 2021
Please find the link below to the most recent publication from NICE outlining Interim treatment change options during the COVID-19 pandemic issued on.  It is endorsed by NHS England. Some of options proposed for multiple myeloma are:
- Allow oral pomalidomide with dexamethasone as second- or third-line therapy instead of intravenous treatments in patients previously treated with lenalidomide to reduce the need for chemotherapy and reduce admissions and risk of neutropenia.
- Allow first-line lenalidomide and dexamethasone for transplant eligible myeloma patients in preference to regimens that require more hospital attendances and parenteral administrations to reduce toxicity of treatment and number of admissions required for treatment.
- Allow second-line lenalidomide and dexamethasone for patients who have not been previously treated with bortezomib.
Please see link below to access the full document.
Interim treatment change options during the COVID-19 pandemic, endorsed by NHS EnglandÂ
UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak
It is clear that the current outbreak is going to impact the ability to deliver healthcare for some months to come. This is especially the case for systemic anti-cancer therapy.
To try and mitigate the impact of changing capacity, and to minimise the risk that the immunosppressive effects of myeloma therapy has, the guidance in the below document has been compiled on 25th March 2020 to help support myeloma doctors in their decision-making and treatment planning.
Find out more
Annual Report
Click here to visit our Annual Report page.
Position Statement
Find out more about our Position Statements by clicking here.